Balancing malaria control efforts with patient safety will require expanded pre-treatment screening, alternative drug regimens, and the development of G6PD-safe antimalarial therapies (Ciavarella et al., 2025; Sulistyaningrum et al., 2020; Watson et al., 2017; Chu et al., 2018). The gene discussed is G6PD; the disease is malaria.